Cited by 1,506Atrial Fibrillation Management and OutcomesCardiac Valve Diseases and TreatmentsVenous Thromboembolism Diagnosis and Management

The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.

Dabigatran versus Warfarin in Patients with Mechanical Heart Valves

Eikelboom, John W., Connolly, Stuart J., Brueckmann, Martina, Granger, Christopher B., Kappetein, Arie P., Mack, Michael J., Blatchford, Jon, Devenny, Kevin, Friedman, Jeffrey, Guiver, Kelly, Harper, Ruth, Khder, Yasser, Lobmeyer, Maximilian T., Maas, Hugo, Voigt, Jens-Uwe, Simoons, Maarten L., Van de Werf, Frans·2013·New England Journal of Medicine

DOI 10.1056/nejmoa1300615

Open this paper in CoChat — free account

Abstract

BACKGROUND: Dabigatran is an oral direct thrombin inhibitor that has been shown to be an effective alternative to warfarin in patients with atrial fibrillation. We evaluated the use of dabigatran in patients with mechanical heart valves. METHODS: In this phase 2 dose-validation study, we studied two populations of patients: those who had undergone aortic- or mitral-valve replacement within the past 7 days and those who had undergone such replacement at least 3 months earlier. Patients were randomly assigned in a 2:1 ratio to receive either dabigatran or warfarin. The selection of the initial dabigatran dose (150, 220, or 300 mg twice daily) was based on kidney function. Doses were adjusted to obtain a trough plasma level of at least 50 ng per milliliter. The warfarin dose was adjusted to obtain an international normalized ratio of 2 to 3 or 2.5 to 3.5 on the basis of thromboembolic risk. The primary end point was the trough plasma level of dabigatran. RESULTS: The trial was terminated prematurely after the enrollment of 252 patients because of an excess of thromboembolic and bleeding events among patients in the dabigatran group. In the as-treated analysis, dose adjustment or discontinuation of dabigatran was required in 52 of 162 patients (32%). Ischemic or unspecified stroke occurred in 9 patients (5%) in the dabigatran group and in no patients in the warfarin group; major bleeding occurred in 7 patients (4%) and 2 patients (2%), respectively. All patients with major bleeding had pericardial bleeding. CONCLUSIONS: The use of dabigatran in patients with mechanical heart valves was associated with increased rates of thromboembolic and bleeding complications, as compared with warfarin, thus showing no benefit and an excess risk. (Funded by Boehringer Ingelheim; ClinicalTrials.gov numbers, NCT01452347 and NCT01505881.).

Integrity signals

Registry

Crossref · 10.1056/nejmoa1300615

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients
Schulman, S., & Kearon, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,025
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients
Schulman, S., Angerås, U., Bergqvist, D., ERIKSSON, B., Lassen, M. R., & FISHER, W. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,761
Guidelines on the management of valvular heart disease (version 2012)
Authors/Task Force Members, Vahanian, A., Alfieri, O., Andreotti, F., Antunes, M. J., Barón-Esquivias, G., Baumgartner, H., Borger, M. A., Carrel, T. P., De Bonis, M., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs109 · Cited by 3,559
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,070
Oral Anticoagulant Therapy
Ageno, W., Gallus, A. S., Wittkowsky, A. K., Crowther, M. A., Hylek, E. M., & Palareti, G. (2012) · CHEST Journal · doi:10.1378/chest.11-2292 · Cited by 1,583
Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium
Leon, M. B., Piazza, N., Nikolsky, E., Blackstone, E. H., Cutlip, D. E., Kappetein, A. P., Krucoff, M. W., Mack, M. J., Mehran, R., Miller, D. C., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehq406 · Cited by 1,217
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited
Watson, T., Shantsila, E., & Lip, G. Y. H. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60040-4 · Cited by 1,124

Flagged first, then by citations

Show all 27 references

1 of the 27 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Dewanjee MK, 1999, J Heart Valve Dis, 8, 324

Sorted by citations

Items 401–500 of 1,000

Recombinant Heparin—New Opportunities
Glass, C. A. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00341 · Cited by 22
“There are also clinical situations where heparin may be preferable, such as for patients with prosthetic heart valves as NOA have greater risks of valve thrombosis (14, 15), pregnancy where there is a lack of clinical experience (16–18), renal impairment as NOAs are renally excreted (19), severe liver diseases as NOAs…”
Background
Non-Vitamin K Antagonist Oral Anticoagulants in Adult Congenital Heart Disease.
Mongeon, F., Macle, L., Beauchesne, L., Bouma, B., Schwerzmann, M., Mulder, B., & Khairy, P. (2019) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.06.022 · Cited by 18
Management of Anticoagulation in Pregnant Women With Mechanical Heart Valves
Daughety, M. M., Zilberman-Rudenko, J., Shatzel, J., McCarty, O., Raghunathan, V., & Deloughery, T. (2020) · Obstetrical and Gynecological Survey · doi:10.1097/ogx.0000000000000751 · Cited by 15
Direct oral anticoagulants versus vitamin K antagonists for cerebral venous thrombosis (DOAC-CVT): an international, prospective, observational cohort study
van de Munckhof, A. A. G. A., van Kammen, M. S., Tatlisumak, T., Krzywicka, K., Aaron, S., Antochi, F. A., Araúz, A., Barboza, M. A., Conforto, A. B., Contreras, D. G., et al. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00519-2 · Cited by 21
Periprocedural antithrombotic therapy during various types of percutaneous cardiovascular interventions
Widimský, P., Kočka, V., Roháč, F., & Osmancik, P. P. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv053 · Cited by 21
Non-valvular atrial fibrillation
Boriani, G., Cimaglia, P., Fantecchi, E., Mantovani, V., Ziacchi, M., Valzania, C., Martignani, C., Biffi, M., & Diemberger, I. (2015) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000236 · Cited by 21
Review of Medical Therapies for the Management of Pulmonary Embolism
Panahi, L., Udeani, G., Horseman, M. A., Weston, J. S., Samuel, N. G., Joseph, M., Mora, A., & Bazan, D. Z. (2021) · Medicina · doi:10.3390/medicina57020110 · Cited by 21
Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease
Fanaroff, A. C., Vora, A. N., & Lópes, R. D. (2022) · European Heart Journal Supplements · doi:10.1093/eurheartj/suab151 · Cited by 22
“Based on the results from these subanalyses, European Society of Cardiology guidelines recommend NOACs in preference to VKAs in patients with AF and aortic stenosis, aortic regurgitation, or mitral regurgitation (Class I, Level of Evidence (LOE) A).31 American College of Cardiology/American Heart Association (ACC/AHA)…”
BackgroundMethodInfluential
Factor XI/XIa Inhibition: The Arsenal in Development for a New Therapeutic Target in Cardio- and Cerebrovascular Disease
Badimón, J. J., Escolar, G., & Zafar, M. U. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9120437 · Cited by 21
“Some DOAC trials in patients with devices were terminated due to higher thrombotic and bleeding events in treated patients [93], while others were stopped due to safety reasons (NCT02872649).”
Background
Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?
Dzeshka, M. S., & Lip, G. Y. H. (2014) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2014.10.017 · Cited by 21
Resuming anticoagulant therapy after intracerebral bleeding
Becattini, C., Sembolini, A., & Paciaroni, M. (2016) · Vascular Pharmacology · doi:10.1016/j.vph.2016.05.012 · Cited by 22
Stroke Prevention in Atrial Fibrillation
Mtwesi, V., & Amit, G. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2019.05.006 · Cited by 21
Quality of Warfarin Therapy and Quality of Life are Improved by Self-Management for Two Years
Sølvik, U. Ø., Løkkebø, E. S., Kristoffersen, A. H., Brodin, E. E., Averina, M., & Sandberg, S. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1693703 · Cited by 21
Non‐vitamin K oral anticoagulants versus warfarin for left atrial appendage thrombus resolution in nonvalvular atrial fibrillation or flutter
Hussain, A., Katz, W. E., Genuardi, M. V., Bhonsale, A., Jain, S. K., Kancharla, K., Saba, S., Shalaby, A. A., Voigt, A., & Wang, N. C. (2019) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.13765 · Cited by 21
2024 ACC/AHA Clinical Performance and Quality Measures for Adults With Valvular and Structural Heart Disease
Jneid, H. M., Chikwe, J., Arnold, S. V., Bonow, R. O., Bradley, S. M., Chen, E. P., Diekemper, R. L., Fugar, S., Johnston, D. R., Kumbhani, D. J., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.006 · Cited by 21
Advances in oral anticoagulation therapy – What's in the pipeline?
Rao, S., & Burkart, T. A. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.02.002 · Cited by 20
Use of Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombi: A Systematic Review
Sedhom, R., Abdelmaseeh, P., Megaly, M. S., & ASINGER, R. W. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.05.012 · Cited by 20
Analysis of Anticoagulation Therapy and Anticoagulation-Related Outcomes Among Asian Patients After Mechanical Valve Replacement
Huang, J.-T., Chan, Y., Wu, V. C., Cheng, Y., Chen, D., Lin, C., Hung, K., Chang, S., Chu, P., Chou, A., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.46026 · Cited by 20
Safety and Effectiveness of Direct Oral Anticoagulants Versus Warfarin for Treating Left Ventricular Thrombus
Herald, J., Goitia, J. J., Duan, L., Chen, A., & Lee, M. S. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00533-w · Cited by 20
Outcomes of Patients with a Mechanical Heart Valve and Poor Anticoagulation Control on Warfarin
Johansson, I., Benz, A. P., Kovalova, T., Balasubramanian, K., Fukakusa, B., Lynn, M. J., Nair, N., Sikder, O., Patel, K., Gayathri, S., et al. (2023) · Thrombosis and Haemostasis · doi:10.1055/s-0043-1777827 · Cited by 20
Anticoagulation management of left ventricular assist devices
Connors, J. M. (2014) · American Journal of Hematology · doi:10.1002/ajh.23836 · Cited by 20
Determination of dabigatran in plasma, serum, and urine samples: comparison of six methods
Du, S., Weiß, C., Christina, G., Krämer, S., Wehling, M., Krämer, R., & Harenberg, J. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-0991 · Cited by 20
Direct oral anticoagulants: unique properties and practical approaches to management
Barnes, G. D., & Kurtz, B. (2016) · Heart · doi:10.1136/heartjnl-2015-309075 · Cited by 20
Pharmacological treatments of cardiovascular diseases: Evidence from real-life studies
Salvo, F., Bezin, J., Bosco‐Lévy, P., Létinier, L., Blin, P., Pariente, A., & Moore, N. D. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.006 · Cited by 24
New Oral Anticoagulants and Their Reversal Agents
Morotti, A., & Goldstein, J. N. (2016) · Current Treatment Options in Neurology · doi:10.1007/s11940-016-0430-5 · Cited by 21
Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol
Calderone, A., Stevens, W., Prior, D., Nandurkar, H. H., Gabbay, E., Proudman, S., Williams, T. J., Celermajer, D. S., Sahhar, J., Wong, P. K. K., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-011028 · Cited by 20
Protocol, rationale and design of DAbigatran for Stroke PreVention In Atrial Fibrillation in MoDerate or Severe Mitral Stenosis (DAVID-MS): a randomised, open-label study
Zhou, M., Chan, E. W., Hai, J. J., Wong, C., Lau, Y. M., Huang, D., Lam, C. C. S., Tam, C. C., Wong, Y. T. A., Yung, S. Y. A., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-038194 · Cited by 21
New Oral Anticoagulants in Nonvalvular Atrial Fibrillation
Fatima, U., Kulkarni, A., Stapleton, D. D., & Kaluski, E. (2016) · Clinical Cardiology · doi:10.1002/clc.22582 · Cited by 19
New Oral Anticoagulants Versus Warfarin in Atrial Fibrillation After Early Postoperative Period in Patients With Bioprosthetic Aortic Valve
Mannacio, V. A., Mannacio, L., Antignano, A., Mauro, C., Mastroroberto, P., Musumeci, F., Zebele, C., & Iannelli, G. (2021) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2021.03.016 · Cited by 19
Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic valves: A meta-analysis
Yokoyama, Y., Briasoulis, Α., Ueyama, H. A., Mori, M., Iwagami, M., Misumida, N., Takagi, H., & Kuno, T. (2021) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2021.07.034 · Cited by 20
Optimal management of cardiac surgery patients using direct oral anticoagulants: recommendations for clinical practice
Heuts, S., Ceulemans, A., Kuiper, G. J. A. J. M., Schreiber, J., van Varik, B. J., Olie, R. H., Cate, H. T., Maessen, J. G., Milojevic, M., & Maesen, B. A. E. (2023) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezad340 · Cited by 19
Oral anticoagulation in patients with left ventricular thrombus: a systematic review and meta-analysis
Haller, P. M., Kazem, N., Agewall, S., Borghi, C., Ceconi, C., Dobrev, D., Cerbai, E., Grove, E. L., Kaski, J. C., Lewis, B. S., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae042 · Cited by 20
The Association of Direct Thrombin Inhibitor Anticoagulants With Cardiac Thromboses
Davidson, B. L. (2014) · CHEST Journal · doi:10.1378/chest.14-2028 · Cited by 19
Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification
Bisson, A., Bodin, A., Clémenty, N., Bernard, A., Babuty, D., Lip, G. Y. H., & Fauchier, L. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.03.017 · Cited by 19
Anticoagulation in the cardiac patient: A concise review
Larson, E. A., German, D. M., Shatzel, J. J., & DeLoughery, T. G. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13171 · Cited by 22
Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis (ARM‐DVT): Methods of a prospective single‐arm management study
Woller, S. C., Stevens, S. M., Johnson, S. A., Bledsoe, J. R., Galovic, B., Lloyd, J. F., Wilson, E. L., Armbruster, B. P., & Evans, R. S. (2019) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12208 · Cited by 18
Left Ventricular Thrombus Therapy With Direct Oral Anticoagulants Versus Vitamin K Antagonists: A Systematic Review and Meta-Analysis
Saleiro, C., Lopes, J., Campos, D. D., Puga, L., Costa, M. A. D. S., Gonçalves, L. M. M., & Teixeira, R. P. (2020) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420977567 · Cited by 19
A direct thrombin inhibitor suppresses protein C activation and factor Va degradation in human plasma: Possible mechanisms of paradoxical enhancement of thrombin generation
Kamisato, C., Furugohri, T., & MORISHIMA, Y. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.03.005 · Cited by 19
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement
Martin, A., Smadja, D. M., & Karam, N. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2017351 · Cited by 19
Restarting and timing of oral anticoagulation after traumatic intracranial hemorrhage: a review and summary of ongoing and planned prospective randomized clinical trials
King, B. T., Milling, T. J., Gajewski, B. J., Costantini, T. W., Wick, J., Price, M. A., Mudaranthakam, D. P., Stein, D. M., Connolly, S. J., Valadka, A. B., et al. (2020) · Trauma Surgery & Acute Care Open · doi:10.1136/tsaco-2020-000605 · Cited by 18
A new strategy for anticoagulation: The factor XI inhibitors
Vedovati, M. C., Becattini, C., & Agnelli, G. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.08.001 · Cited by 19
Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin
Furugohri, T., & MORISHIMA, Y. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.06.034 · Cited by 18
Antikoagulation bei Patienten mit chronischer Niereninsuffizienz
Schlieper, G., Schwenger, V., Remppis, A., Keller, T., Dechend, R., Maßberg, S., Baldus, S. E., Weinreich, T., Hetzel, G. R., Floege, J., et al. (2017) · Der Internist · doi:10.1007/s00108-017-0220-5 · Cited by 19
Effects of rivaroxaban and dabigatran on local expression of coagulation and inflammatory factors within human aortic stenotic valves
Wypasek, E., Natorska, J., Mazur, P. K., Kopytek, M., Gawęda, B., Kapusta, P., Madeja, J., Iwaniec, T., Kapelak, B., & Undas, A. (2020) · Vascular Pharmacology · doi:10.1016/j.vph.2020.106679 · Cited by 19
The use of direct oral anticoagulants in patients with ventricular assist devices: Is there hope for Factor Xa inhibition?
Meredith, T., Schnegg, B., & Hayward, C. (2020) · Artificial Organs · doi:10.1111/aor.13848 · Cited by 18
Off-label Use for Direct Oral Anticoagulants: Valvular Atrial Fibrillation, Heart Failure, Left Ventricular Thrombus, Superficial Vein Thrombosis, Pulmonary Hypertension—a Systematic Review
Brokmeier, H. M., & Kido, K. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020970618 · Cited by 18
Analysis of microRNA signatures in ischemic stroke thrombus
Kim, J., Byun, J. S., Kim, J., Park, M., Hong, S. A., Nam, T.-K., Choi, H. H., Hong, S., Han, S., Jeong, H.-B., et al. (2021) · Journal of NeuroInterventional Surgery · doi:10.1136/neurintsurg-2021-017597 · Cited by 18
Socioeconomic Status and Risk of Bleeding After Mechanical Aortic Valve Replacement
Dalén, M., Persson, M., Glaser, N., & Sartipy, U. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.04.030 · Cited by 18
Potential use of NOACs in developing countries: pros and cons
Bista, D., Chalmers, L., Bereznicki, L., & Peterson, G. M. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1693-y · Cited by 18
Direct oral anticoagulants: integration into clinical practice
Cowell, R. P. W. (2014) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2013-132474 · Cited by 19
Improving the hemocompatibility of biomedical polymers
Amoako, K. A., & Gbyli, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-08-100497-5.00016-1 · Cited by 18
Comparison of Anticoagulant Therapy for Atrial Fibrillation - Novel Oral Anticoagulants Versus Vitamin K Antagonists
Chen, S. T., & Patel, M. R. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.01.005 · Cited by 20
Expanding use of new oral anticoagulants
Weitz, J. I. (2014) · F1000Prime Reports · doi:10.12703/p6-93 · Cited by 17
Antithrombotic treatment and intracerebral haemorrhage: between Scylla and Charybdis
Hofmeijer, J., Kappelle, L. J., & Klijn, C. J. M. (2015) · Practical Neurology · doi:10.1136/practneurol-2015-001104 · Cited by 17
Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study
Oskarsdottir, A. R., Guðmundsdóttir, B. R., Jensdottir, H. M., Flygenring, B., Pálsson, R., & Onundarson, P. T. (2021) · Blood · doi:10.1182/blood.2020008698 · Cited by 17
Eighty years of oral anticoagulation: Learning from history
Montinari, M. R., Minelli, S., & Caterina, R. D. (2021) · Vascular Pharmacology · doi:10.1016/j.vph.2021.106918 · Cited by 20
Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum
Lüscher, T. F., Davies, A., Beer, J. H., Valgimigli, M., Nienaber, C. A., Camm, A. J., Baumgärtner, I., Diener, H., & Konstantinides, S. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab642 · Cited by 18
Oral anticoagulation challenges and therapeutic dilemmas in the very elderly: to treat and how to treat octogenarians and nonagenarians?
Papazoglou, Α. S., Moysidis, D. V., Κάρτας, Α., Bekiaridou, Α., Samaras, A., & Giannakoulas, G. A. (2023) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16508 · Cited by 19
2024 ACC/AHA Clinical Performance and Quality Measures for Adults With Valvular and Structural Heart Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Performance Measures
Jneid, H. M., Chikwe, J., Arnold, S. V., Bonow, R. O., Bradley, S. M., Chen, E. P., Diekemper, R. L., Fugar, S., Johnston, D. R., Kumbhani, D. J., et al. (2024) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000129 · Cited by 27
Left Atrial Appendage Closure with Transcatheter-Delivered Devices
Whisenant, B. K., & Weiß, P. J. (2014) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2014.01.002 · Cited by 17
Self-management of Oral Anticoagulation
Siebenhofer, A., Jeitler, K., Horvath, K., Habacher, W., Schmidt, L., & Semlitsch, T. (2014) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2014.0083 · Cited by 17
“This was documented in the study evaluating dabigatran in patients with mechanical heart valves which was terminated early (25).”
Background
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons WRITING COMMITTEE MEMBERS*
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O’Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Cited by 17
Computational simulation and comparison of prothrombin complex concentrate dosing schemes for warfarin reversal in cardiac surgery
Tanaka, K. A., Mazzeffi, M. A., Strauss, E. R., Szlam, F., & Guzzetta, N. A. (2016) · Journal of Anesthesia · doi:10.1007/s00540-015-2128-3 · Cited by 17
Use of Anticoagulants in Patients with Pulmonary Hypertension
Bertoletti, L., Mismetti, V., & Giannakoulas, G. A. (2020) · Hämostaseologie · doi:10.1055/a-1171-3995 · Cited by 17
RIvaroxaban in mitral stenosis (RISE MS): A pilot randomized clinical trial
Sadeghipour, P., Pouraliakbar, H., Parsaee, M., Shojaeifard, M., Farrashi, M., Jamalkhani, S., Beheshti, A. T., Rostambeigi, S., Meimand, S. E., Firouzi, A., et al. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.03.037 · Cited by 17
Role of thromboelastography and rapid thromboelastography to assess the pharmacodynamic effects of vitamin K antagonists
Franchi, F., Hammad, J. S., Rollini, F., Tello‐Montoliu, A., Patel, R., Darlington, A., Kraemer, D. F., Cho, J. R., DeGroat, C., Bhatti, M., et al. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1130-1 · Cited by 17
Management of acute intracerebral haemorrhage – an update
Law, Z. K., Appleton, J. P., Bath, P. M., & Sprigg, N. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-2-166 · Cited by 18
Antithrombotic Management of Patients With Prosthetic Heart Valves
Sanaani, A., Yandrapalli, S., & Harburger, J. M. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000189 · Cited by 13
Comparing clinical outcomes of NOACs with warfarin on atrial fibrillation with Valvular heart diseases: a meta-analysis
He, Q., Sze, C.-Y., Shum, T.-Y., Hao, G., Wong, N.-Y. B., Sin, T., Wei, W., & Xia, S. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-1089-0 · Cited by 17
“the control group [22], and hence, the trial was terminated prematurely in phase 2 [23] and subjects implanted with mechanical valve were excluded in most of NOAC-related trials [8, 10, 19, 20].”
Background
Dabigatran in Patients with Mechanical Heart Valves
Eikelboom, J. W., Brueckmann, M., & de Werf, F. V. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1315004 · Cited by 17
AB023, A Novel Antibody That Binds Factor XI and Blocks Its Activation by Factor XIIa
Chan, N., & Weitz, J. I. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312459 · Cited by 17
L’anticoagulation dans la fibrillation atriale du sujet âgé : point de vue du gériatre avec un focus sur les anticoagulants oraux directs
Vogel, T., Gény, B., Kaltenbach, G., & Lang, P. O. (2014) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2014.08.005 · Cited by 15
Structural and cellular basis of vitamin K antagonism
Liu, S., Shen, G., & Li, W. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15800 · Cited by 16
Evolving technology: the TRIFLO tri-leaflet mechanical valve without oral anticoagulation: a potential major innovation in valve surgery
Carrel, T. P., Vogt, P. R., Obrist, D., & Schaff, H. V. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1220633 · Cited by 16
“The trial was stopped prematurely (20).”
Left Atrial Appendage Occlusion and Post-procedural Antithrombotic Management
Kramer, A. D., Patti, G., Nielsen‐Kudsk, J. E., Berti, S. L., & Korsholm, K. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030803 · Cited by 16
“However, a potential caution of a DOAC-based approach after structural heart interventions was raised after discouraging results from the randomized GALILEO trial on transcatheter aortic valve implantation [60,61].”
Result
Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence
Zalpour, A., & Oo, T. H. (2015) · Advances in Hematology · doi:10.1155/2015/920361 · Cited by 15
Targeting the Contact Pathway of Coagulation for the Prevention and Management of Medical Device-Associated Thrombosis
Goel, A., Tathireddy, H., Wang, S., Vu, H. H., Puy, C., Hinds, M. T., Zonies, D. H., McCarty, O. J. T., & Shatzel, J. J. (2023) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0043-57011 · Cited by 16
Direct oral anticoagulants: a guide for daily practice
Fontana, P., Robert‐Ebadi, H., Bounameaux, H., Boehlen, F., & Righini, M. (2016) · Swiss Medical Weekly · doi:10.4414/smw.2016.14286 · Cited by 17
Gastrointestinal bleeding in patients receiving antiplatelet and anticoagulant therapy: practical guidance for restarting therapy and avoiding recurrences.
Pipilis, A. G., Makrygiannis, S. S., Chrisanthopoulou, E., Sourlas, N., Kaliambakos, S., & Ntailianas, P. (2014) · PubMed · Cited by 16
Anticoagulation for prosthetic heart valves
Yanagawa, B., Whitlock, R. P., Verma, S., & Gersh, B. J. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000259 · Cited by 17
Anticoagulation After Heart Valve Replacement or Transcatheter Valve Implantation
Carnicelli, A., O’Gara, P. T., & Giugliano, R. P. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.07.048 · Cited by 16
Incidence and predictors of excessive warfarin anticoagulation in patients with atrial fibrillation—The EWA study
Jaakkola, S., Nuotio, I. O., Kiviniemi, T., Virtanen, R., Issakoff, M., & Airaksinen, J. K. E. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175975 · Cited by 16
Oral anticoagulation and left atrial thrombi resolution in nonrheumatic atrial fibrillation or flutter: A systematic review and meta‐analysis
Wang, N. C., Sather, M. D., Hussain, A., Althouse, A. D., ADELSTEIN, E. C., Jain, S. K., Katz, W. E., Shalaby, A. A., Voigt, A., & Saba, S. (2018) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.13368 · Cited by 16
Dental management of patients on anti-thrombotic agents
Lee, J. K. (2018) · 대한구강악안면외과학회지 · doi:10.5125/jkaoms.2018.44.4.143 · Cited by 17
Non–Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation
Fanaroff, A. C., & Ohman, E. M. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-042617-092334 · Cited by 16
Procedures and Outcomes of Surgical Aortic Valve Replacement in Adults
Mazine, A., & El-Hamamsy, I. (2019) · Cardiology Clinics · doi:10.1016/j.ccl.2019.09.012 · Cited by 16
Valvular heart disease among non-valvular atrial fibrillation: a misnomer, in search of a new term
Breithardt, G., & Baumgartner, H. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv193 · Cited by 16
“available trial data has been shown by the RE-ALIGN study which advises against the use of the NOAC dabigatran in patients with mechanical heart valve prostheses.(12)”
Method
Anticoagulation management in adult patients with congenital heart disease: a narrative review
Sinning, C., Zengin, E., Blankenberg, S., Rickers, C., Kodolitsch, Y. V., Diller, G., & Kirchhof, P. F. (2021) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-631 · Cited by 15
Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward!
Abdelnabi, M. H., Benjanuwattra, J., Okasha, O., Almaghraby, A. M., Saleh, Y., & Gerges, F. (2022) · The Egyptian Heart Journal · doi:10.1186/s43044-022-00259-9 · Cited by 16
Trends in SAVR with biological vs. mechanical valves in middle-aged patients: results from a French large multi-centric survey
Caus, T., Chabry, Y., Nader, J., Fusellier, J. F., Brux, J. L. D., & for the EpiCard investigators (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1205770 · Cited by 17
“Mechanical prosthetic valves (MPVs), for which oral direct Factor Xa inhibitors failed to be a valid option (2, 3), are not generally considered in patients above 65 years-old, even if a long-standing anticoagulant therapy is required and despite the fact that acceptable outcomes with a MPV may be achieved in selected…”
Background
Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice
Kalabalik, J., Rattinger, G. B., Sullivan, J., Slugocki, M., Carbone, A. M., & Rivkin, A. M. (2015) · Drugs · doi:10.1007/s40265-015-0405-y · Cited by 15
“Response to dabigatran etexilate has high inter-individual variability and monitoring trough levels may identify poor responders [31].”
Background
Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses
Spencer, R. J., & Amerena, J. V. (2015) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0127-2 · Cited by 16
“However, the one study to examine the use of NOACs in these patients showed dabigatran was associated with increased rates of thromboembolic and bleeding complications, as compared with warfarin [27].”
The New Direct Oral Anticoagulants in Special Indications: Rationale and Preliminary Data in Cancer, Mechanical Heart Valves, Anti-phospholipid Syndrome, and Heparin-Induced Thrombocytopenia and Beyond
Alberio, L. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.03.002 · Cited by 16
Development of Recommendations to Continue Anticoagulation with One of the Two Types of Oral Anticoagulants Based on the Identification of Patients' Preference
Zolfaghari, S., Frölich, L., Weiß, C., Wehling, M., Wild, P. S., Prochaska, J. H., Beyer‐Westendorf, J., Koscielny, J., Lip, G. Y. H., & Harenberg, J. (2015) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0035-1546467 · Cited by 15
A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin
Stambler, B. S. (2013) · International Archives of Medicine · doi:10.1186/1755-7682-6-46 · Cited by 16
Thrombosis, Hypercoagulable States, and Anticoagulants
Hollenhorst, M. A., & Battinelli, E. M. (2016) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2016.07.001 · Cited by 15
e‐Health‐based management of patients receiving oral anticoagulation therapy: results from the observational thrombEVAL study
Prochaska, J. H., Göbel, S., Keller, K., Coldewey, M., Ullmann, A., Lamparter, H., Schulz, A., Schinzel, H., Bickel, C., Lauterbach, M., et al. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13727 · Cited by 15
Review of Direct Oral Anticoagulants and Guide for Effective Drug Utilization
Khachatryan, T., Hauschild, C., Hoff, J., Contractor, T. A., Khachatryan, A., Tran, H. N., Matsuo, B., Jacobson, A. K., & Hilliard, A. A. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00344-6 · Cited by 15
“The RE-ALIGN study evaluating dabigatran compared with warfarin in patients with mechanical aortic and mitral valves found higher rates of thromboembolic and bleeding events with dabigatran, leading to the early termination of the study [28].”
Background
Noncanonical Effects of Oral Thrombin and Factor Xa Inhibitors in Platelet Activation and Arterial Thrombosis
Polzin, A., Dannenberg, L., Thienel, M., Orban, M., Wolff, G., Hohlfeld, T., Zeus, T., Kelm, M., & Petzold, T. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1716750 · Cited by 16
Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition
Mavromanoli, A. C., Barco, S., & Konstantinides, S. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12509 · Cited by 15

Authors: Eikelboom, J. W., Connolly, S. J., Brueckmann, M., Granger, C. B., Kappetein, A. P., Mack, M. J., Blatchford, J., Devenny, K., Friedman, J., Guiver, K., Harper, R., Khder, Y., Lobmeyer, M. T., Maas, H., Voigt, J.-U., Simoons, M. L., & Van de Werf, F.
Affiliations: Hamilton Health Sciences (CA)
Boehringer Ingelheim (Germany) (DE)
Duke University (US)
Erasmus MC (NL)
Heart Hospital Baylor Plano (US)
Boehringer Ingelheim (United Kingdom) (GB)
Boehringer Ingelheim (United States) (US)
Boehringer Ingelheim (France) (FR)
KU Leuven (BE)
ORCID: Eikelboom, John W.
Connolly, Stuart J.
Brueckmann, Martina
Granger, Christopher B.
Kappetein, Arie P.
Mack, Michael J.
Blatchford, Jon
Guiver, Kelly
Khder, Yasser
Lobmeyer, Maximilian T.
Voigt, Jens-Uwe
Simoons, Maarten L.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2013-09-26
Volume: 369
Issue: 13
Pages: 1206-1214
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1300615
OpenAlex: W2016875529
Cited by: 1,506
References: 27
Citations by year: 2026: 52 · 2025: 84 · 2024: 111 · 2023: 95 · 2022: 102 · 2021: 140 · 2020: 130 · 2019: 113 · 2018: 119 · 2017: 128 · 2016: 116 · 2015: 131 · 2014: 147 · 2013: 36
FWCI: 97.35
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords: dabigatran, warfarin, mechanical heart valves, direct thrombin inhibitors, anticoagulation, thromboembolism, bleeding complications, pericardial bleeding, stroke, aortic valve replacement, mitral valve replacement, dose adjustment
MeSH terms: Dabigatran, Aged, Anticoagulants, Atrial Fibrillation, Benzimidazoles, Female, Heart Valve Prosthesis, Hemorrhage, Humans, Male, Middle Aged, Thromboembolism, Warfarin, beta-Alanine, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dabigatran versus Warfarin in Patients with Mechanical Heart Valves

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks